Sexual Health Market to surpass US$ 14.1 Billion by 2027 - Coherent Market Insights

Global Sexual Health Market, by Product Type (Erectile Dysfunction Drugs, Gender Dysphoria Drugs, Hypoactive Sexual Desire Disorder Drugs, Premature Ejaculation Drugs, and Others), by Gender (Male and Female), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) is estimated to be valued at US$  10,289.5 million in 2019, and is expected to exhibit a CAGR of 4.2%, during the forecast period (2019-2027), as highlighted in a new report published by Coherent Market Insights.

Major players in the pharmaceutical industry are focusing on introducing various drugs for treating sexual dysfunction, which is expected to drive growth of the sexual health market. For instance, in 2017, Teva Pharmaceutical Industries Ltd. announced the launch of generic version of Viagra (sildenafil citrate) tablets in the U.S. indicated for the treatment of erectile dysfunction. Moreover, in September 2019, Lupin Limited announced the launch of Sildenafil tablets, a generic version of Pfizer Inc.’s Viagra tablets in the U.S. indicated for the treatment of erectile dysfunction.

Browse 35 Market Data Tables and 31 Figures spread through 167 Pages and in-depth TOC on 'Global Sexual Health Market, by Product Type (Erectile Dysfunction Drugs, Gender Dysphoria Drugs, Hypoactive Sexual Desire Disorder Drugs, Premature Ejaculation Drugs, and Others), by Gender (Male, and Female), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies),, and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Global Forecast to 2027'

To know the latest trends and insights related to Global Sexual Health Market, click the link below:

https://www.coherentmarketinsights.com/market-insight/sexual-health-market-3364

The sexual health market is expected to witness robust growth owing to increasing initiatives by major players operating in the market. These players are engaged in adoption of inorganic growth strategies such as collaborations and partnerships to distribute their product worldwide, and to increase its consumer base. For instance, in May 2014, Sanofi entered an acquisition agreement with Eli Lilly and Company to acquire the rights from the Eli Lilly and Company to apply for regulatory approval for the nonprescription Cialis (OTC) in the U.S., Europe, Canada and Australia.

Moreover, increasing approval of drugs for improving sexual health is expected to drive the global sexual health market growth during forecast period. For instance, in March 2019, VIVUS, Inc., a biopharmaceutical company, received approval from the Ministry of Health of the Russian Federation for its Avanafil tablet (with strength of 50 mg, 100 mg and 200 mg tablets) for treatment of erectile dysfunction (ED). The product is also approved in Jordan, Saudi Arabia, Turkey and the United Arab Emirates market.

Key Takeaways of the Global Sexual Health Market:

• The global sexual health market is expected to exhibit a CAGR of 4.2% during the forecast period (2019-2027) owing to increasing drug launches for the treatment of sexual dysfunction. For instance, in June 2019, Novitium Pharma LLC receive U.S. FDA approval for its Sildenafil for Oral Suspension, 10mg/mL, (a generic of Pfizer’s Revatio).
• Increasing clinical trials by key players for developing novel treatment option for treating sexual dysfunctions is expected to drive the global sexual health market growth over the forecast period. For instance, in July 31, 2019, Futura Medical Developments Ltd. initiated phase 3 clinical trial to demonstrate the efficacy of various doses of MED2005 (Glyceryl Trinitrate (GTN)) for the treatment of erectile dysfunction, and to evaluate the long-term efficacy and safety (12 months) of MED2005. The study is estimated to complete in October 1, 2020.
• Major players operating in the global sexual health market include Teva Pharmaceutical Industries Ltd., Meda Pharmaceuticals, Inc., Eli Lilly & Company, Bayer AG, Vivus, Inc., Zydus Pharmaceuticals, IVFTECH APS, Merck & Co., Pfizer Inc., Sun Pharmaceutical Industries Ltd., Novartis International AG, Mylan Pharmaceuticals Inc., and AstraZeneca.